Skip to search formSkip to main contentSkip to account menu

tofogliflozin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
ABSTRACT Introduction: Accumulating data from recent studies has altered the gold standard of care for diabetes treatment. In… 
2017
2017
Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
2017
2017
The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study
Background Postprandial hyperglycemia and hyperlipidemia are highly related to the development of atherosclerosis. Sodium/glucose… 
2017
2017
Effect of Tofogliflozin on Cardiac Function: Potential Link Between Ketone Bodies and the Heart
This report describes the effect of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on cardiac function and… 
2016
2016
Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
Background Some patients with type 2 diabetes mellitus (T2DM) on insulin have poor glycemic control and require add-on therapy to… 
Review
2016
Review
2016
Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes
ABSTRACT Introduction: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of drugs that are increasingly used… 
Review
2016
Review
2016
A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production
We read a recent review on the renoprotective effect of sodiumglucose cotransporter 2 inhibitor (SGLT2i) [1], with a great… 
2015
2015
In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human…
Abstract 1. The metabolism and drug–drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co… 
2014
2014
Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
The Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2… 
2013
2013
In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach
To evaluate the relationship between the in vitro and in vivo potency of sodium-glucose cotransporter (SGLT) inhibitors, a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)